Works by Perfetti, Riccardo


Results: 38
    1

    Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia.

    Published in:
    Journal of Clinical Pharmacology, 2025, v. 65, n. 5, p. 575, doi. 10.1002/jcph.6170
    By:
    • Bailey, Evan;
    • Phan, Han;
    • Ahmad, Ayesha;
    • Thomas, Janet;
    • Ames, Elizabeth G.;
    • Pritchard, Amanda B.;
    • Quinonez, Shane C.;
    • Wang, Stella;
    • Dayley, Caleb;
    • Salt, Andrew;
    • Pick, Christina;
    • Durrant, Abe;
    • Johnson, Samuel;
    • Nicodemus‐Johnson, Jessie;
    • Dickson, Samuel P.;
    • Perfetti, Riccardo;
    • Hendrix, Suzanne B.;
    • Shendelman, Shoshana
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12

    Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Activity After Oral Administration of AMG 221, a Selective 11β-HSD1 Inhibitor.

    Published in:
    Journal of Clinical Pharmacology, 2011, v. 51, n. 6, p. 830, doi. 10.1177/0091270010374470
    By:
    • Gibbs, John P.;
    • Emery, Maurice G.;
    • McCaffery, Ian;
    • Smith, Brian;
    • Gibbs, Megan A.;
    • Akrami, Anna;
    • Rossi, John;
    • Paweletz, Katherine;
    • Gastonguay, Marc R.;
    • Bautista, Edgar;
    • Wang, Minghan;
    • Perfetti, Riccardo;
    • Daniels, Oranee
    Publication type:
    Article
    13
    14
    15
    16

    3,5,3'-Triiodo-L-thyronine enhances the differentiation of a human pancreatic duct cell line (hPANC-1) towards a -cell-Like phenotypeSilvia Misiti and Emanuela Anastasi contributed equally to this work.

    Published in:
    Journal of Cellular Physiology, 2005, v. 204, n. 1, p. 286, doi. 10.1002/jcp.20293
    By:
    • Silvia Misiti;
    • Emanuela Anastasi;
    • Salvatore Sciacchitano;
    • Cecilia Verga Falzacappa;
    • Laura Panacchia;
    • Barbara Bucci;
    • Daniele Khouri;
    • Ilaria D'Acquarica;
    • Ercole Brunetti;
    • Umberto Di Mario;
    • Vincenzo Toscano;
    • Riccardo Perfetti
    Publication type:
    Article
    17
    18
    19

    Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.

    Published in:
    Cardiovascular Diabetology, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12933-024-02135-z
    By:
    • Januzzi, James L.;
    • Del Prato, Stefano;
    • Rosenstock, Julio;
    • Butler, Javed;
    • Ezekowitz, Justin;
    • Ibrahim, Nasrien E.;
    • Lam, Carolyn S.P.;
    • Marwick, Thomas;
    • Wilson Tang, W. H.;
    • Liu, Yuxi;
    • Mohebi, Reza;
    • Urbinati, Alessia;
    • Zannad, Faiez;
    • Perfetti, Riccardo
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27

    Rational drug design and PPAR Agonists.

    Published in:
    Current Diabetes Reports, 2005, v. 5, n. 5, p. 340, doi. 10.1007/s11892-005-0091-3
    By:
    • Perfetti, Riccardo;
    • D’Amico, Eugenio
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38

    Propensity‐score‐matched comparative analyses of simultaneously administered fixed‐ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 12, p. 2821, doi. 10.1111/dom.13462
    By:
    • Rosenstock, Julio;
    • Handelsman, Yehuda;
    • Vidal, Josep;
    • Ampudia Blasco, F. Javier;
    • Giorgino, Francesco;
    • Liu, Minzhi;
    • Perfetti, Riccardo;
    • Meier, Juris J.
    Publication type:
    Article